Funding Alert Health Care

Indian home diagnostics firm Inito raises $29m series B

• ByStartupStory     |    December 16, 2025

Indian at-home diagnostics startup Inito has raised $29 million in a Series B round to scale its AI-powered home testing platform beyond fertility into a broader suite of hormone and health diagnostics. The Bengaluru- and Dubai-based company uses AI-designed antibodies to deliver lab-grade results from smartphone-connected test kits, aiming to make advanced diagnostics as routine and convenient as checking blood oxygen or heart rate at home.

Funding details and investors

The $29 million Series B is led by Bertelsmann India Investments (BII), with strong participation from existing backer Fireside Ventures and other investors.
This round lifts Inito’s total equity funding to about $45 million, following its earlier Series A led by Fireside in 2023 and seed capital that helped bring its first fertility product to market.

Co-founders Aayush Rai and Varun AV said the new capital will fuel R&D, expand the testing menu, grow presence in key global markets, and strengthen manufacturing and regulatory capabilities as Inito moves from a single-product company to a full-stack at-home diagnostics platform.

From fertility tracker to full-stack health diagnostics

Inito first gained traction with its smartphone-enabled fertility monitor, which measures multiple hormones in urine to accurately map a woman’s fertile window, ovulation, and cycle health from home.
Building on that base, the company now plans to add tests for a wide range of biomarkers, including:

• Testosterone and other sex hormones

• Thyroid function

• Vitamin levels

• Metabolic and other chronic-condition markers

The vision is to let consumers run a panel of tests at home using a small reader and disposable test strips, with results interpreted by Inito’s AI engine and surfaced in an app that shows trends, explains results in plain language, and flags when to consult a doctor.

AI-engineered antibodies as the core technology

Traditional rapid diagnostic tests rely on animal-derived antibodies that can be variable, harder to scale, and limited in what they can detect.
Inito is instead working with computational protein design and AI-enabled antibody engineering to create synthetic antibodies that are:

• More stable and consistent across manufacturing batches

• Tuned for higher sensitivity and specificity

• Easier to adapt to new biomarkers

This approach is intended to close the gap between lab-based immunoassays and home tests, so users can get clinically reliable numbers without visiting a collection centre or hospital. It also gives Inito a defensible technology moat via patents around its antibody designs, test chemistries, and hardware–software integration.

Global footprint and regulatory positioning

Inito currently operates with teams in Bengaluru, Dubai, and London, targeting India as a core market while also building for the US, Middle East, and Europe.
The company says it already holds more than 20 patents related to at-home diagnostics, and is working through the regulatory pathways needed to launch new tests in multiple geographies (such as US FDA, CE marking, and local device rules).

By pairing a connected reader with app-based intelligence, Inito sits at the intersection of medical devices, digital health, and consumer wellness, an area regulators have increasingly clear frameworks for, especially in fertility and chronic-disease monitoring.

Market context and strategic vision

Hormones influence fertility, mood, metabolism, sleep, and energy, yet most people only get endocrine tests occasionally or when a problem is suspected.
Inito’s founders argue that health care “should start at home,” with regular low-friction testing that helps users and clinicians catch issues earlier and personalize treatment over time.

The Series B round positions Inito to:

• Broaden its product line from fertility into full-spectrum hormone and health diagnostics

• Invest deeper in AI and antibody engineering to keep raising test accuracy

• Scale manufacturing and distribution both in India and overseas

• Build partnerships with telehealth providers, clinicians, and possibly insurers who could integrate at-home data into care pathways

As AI-native healthtech matures, Inito’s model—combining deep biotech (antibodies), hardware, and software into a consumer-friendly package—aims to make advanced diagnostics more continuous, affordable, and accessible, starting from the home rather than the hospital.

Follow Startup Story